What is Eikon Therapeutics, Inc. 's financing cash flow?

Eikon Therapeutics, Inc. (EIKN) reported financing cash flow of $349.31M in Q1 2026.

What does financing cash flow mean?

Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.

MYR GroupMYRG

-$56.35M+13.3%

Dave, Inc.DAVE

-$19.08M+4.1%

Cabot CorporationCBT

-$92M-283%

Travel + LeisureTNL

$7M+111%

UnifirstUNF

-$7.31M+45.2%

HES

Hess MidstreamHESM

-$221.8M-43.0%

Operating income-$87.3M-22.3%

Net income-$83.0M-21.6%

EPS (diluted)-$2.46+90.9%

Cash & equivalents$161.2M-21.2%

Total debt$254.8M—

Total equity$550.7M+186%

Total assets$850.8M—

Operating cash flow-$89.8M-64.7%

CapEx$262.0K-98.8%

Free cash flow-$90.1M-17.1%

Market cap$514.86M—

Reported directly by Eikon Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInFinancingActivities.

The official record: Eikon Therapeutics, Inc. ’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Eikon Therapeutics, Inc. 's financing cash flow?: Eikon Therapeutics, Inc. (EIKN) reported financing cash flow of $349.31M in Q1 2026.
What does financing cash flow mean?: Total net cash provided by or used in financing activities — debt issuance/repayment, equity transactions, and dividend payments.